Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine

Liver

Volumn 17, Issue 2, 1997, Pages 103-106

  Honkoop, Pieter ^a   De Man, Robert A ^a   Zondervan, Pieter E ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral treatment; Hepatitis B; Histology; Lamivudine

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; MALE;

EID: 0030929584     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1997.tb00789.x     Document Type: Article

References (12)

1. DOONG S L, TSAI C H, SCHINAZI R F, LIOTTA D C, CHENG Y C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991: 88: 8495-8499.
2. DE MAN R A, SCHALM S W, MAIN J, et al. A dose ranging study to determine the antiviral activity and safety of lamivudine (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection. Gut 1993: 34(suppl). S5.
3. DIENSTAG J L, PERRILLO R P, SCHIFF E R, BARTHOLOMEW M, VICARY C, RUBIN M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995: 333: 1657-1661.
4. FATTOVICH G, RUGGE M, BROLLO L, PONTISSO P, NOVENTA F, GUIDO M, ALBERTI A, REALDI G. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986. 6: 167-172.
5. TYRRELL D L J, MITCHELL M C, DE MAN R A, ET AL. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993: 18: 112A
6. NEVENS F, TYRELL D L, DE MAN R A. et al. A six months dose ranging study of the safety and efficacy of lamivudine in chronic hepatitis B. J Hepatol 1995: 23(S1): 91.
7. KNODELL R G, ISHAK K G, BLACK W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1981: 1: 431-435.
8. DESMET V J, GERBER M, HOOFNAGLE J H, MANNS M, SCHEUER P J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994: 19: 1513-1520.
9. VAQUER P, CANET R, LLOMPART A, RIERA J, OBRADOR A, GAYA J. Histological evolution of chronic hepatitis C. Factors related to progression. Liver 1994: 14: 265-269.
10. DE JONGH F E, JANSSEN H L, DE MAN R A, HOP W C, SCHALM S W, VAN BLANKENSTEIN M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992: 103: 1630-1635.
11. FATTOVICH G, BROLLO L, GIUSTINA G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991: 32: 294-298.
12. KORENMAN J, BAKER B, WAGGONER J, EVERHART J E, DI BISCEGLIE A M, HOOFNAGLE J H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991: 114: 629-634.